Ligand Pharma (LGND) Tops Q4 EPS by 49c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $279.44 +6.59%
Revenue Growth %: +33.3%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +33.3%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.36, $0.49 better than the analyst estimate of $0.87. Revenue for the quarter came in at $50.38 million versus the consensus estimate of $44.09 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- CVG to join Russell 2000 and Russell 3000 indexes June 26
- Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
